Supreme Court toss­es Bris­tol My­er­s' bid to re­vive $1.2B CAR-T case against Gilead

In the lat­est set­back for Bris­tol My­ers Squibb in a years-long le­gal tus­sle with Gilead over a CAR-T patent, the Supreme Court of the Unit­ed States has de­clined to hear its pe­ti­tion to re­vive a $1.2 bil­lion ver­dict.

At its core, Bris­tol My­ers claimed that Gilead’s pi­o­neer­ing CAR-T, Yescar­ta, in­fringed on its patent re­lat­ing to the com­po­si­tion of a chimeric anti­gen re­cep­tor — the CAR in CAR-T — that can be ge­net­i­cal­ly en­gi­neered in­to a T cell.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.